Sequential combination of anti-PD-1 antibody and PEG-IFNα in chronic hepatitis B patients: correlates of HBsAg loss with enhanced T-cell responses

医学 抗体 慢性肝炎 病毒学 乙型肝炎表面抗原 免疫学 乙型肝炎 乙型肝炎病毒 免疫系统 慢性病 单克隆抗体 自身抗体 抗原 病毒 外周血单个核细胞
作者
Hongmin Wang,Chao Zhang,Xiaoying Li,Yaping Li,Xin Zhang,Ruonan Xu,Kaili Wang,Sa Lv,Xing Fan,Qing Wang,Shanquan Liu,Shengxian Yang,Xiaoning Zhang,Shuangsuo Dang,Fu-Sheng Wang,Junliang Fu
出处
期刊:Emerging microbes & infections [Taylor & Francis]
卷期号:15 (1): 2735154-2735154
标识
DOI:10.1080/22221751.2026.2735154
摘要

Pegylated interferon-α (PEG-IFNα) exhibits suboptimal efficacy in achieving a functional cure in patients with chronic hepatitis B (CHB), partially due to impaired hepatitis B virus (HBV)-specific T-cell function. We conducted a pilot study (ClinicalTrials.gov: NCT06457477) to explore the efficacy, safety, and immunological changes associated with a response-guided sequential strategy of anti-PD-1 antibody (αPD-1) and PEG-IFNα. Ten virologically suppressed CHB patients receiving nucleos(t)ide analogues (NAs), all of whom had previously received PEG-IFNα and had HBsAg levels ≤200 IU/mL at enrolment, were included. The patients continued background NA therapy and received αPD-1 (sintilimab) for up to 24 weeks; PEG-IFNα was added at week 12 if HBsAg decline was <1 log10 IU/mL. HBV-specific T-cell responses targeting surface, core, and polymerase peptide pools were quantified, and plasma inflammatory proteins were longitudinally assessed. Nine patients completed the study, and six achieved HBsAg loss: three during NAs plus αPD-1 treatment (Group A) and three after PEG-IFNα add-on (Group B). All six maintained HBsAg negativity 24 weeks after treatment discontinuation. Most adverse events were grade 1–2. Increases in HBV-specific IL-2 and IFN-γ responses were observed in several patients with HBsAg loss, whereas such responses remained limited in nonresponders (Group C). Among 12 prespecified cytokines, IL-10 showed an early longitudinal difference, with higher levels in Group A at week 3. Exploratory analyses showed that week-3 IL-10 was positively associated with early ALT elevation and subsequent HBsAg decline. These findings support further evaluation of response-guided sequential immunotherapy strategies in larger, controlled, and well-characterized cohorts.Trial registration: ClinicalTrials.gov identifier: NCT06457477..
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
xiaozhang完成签到,获得积分20
1秒前
369ninja的应助被Pomelotea采纳,获得10
1秒前
3秒前
3秒前
深情安青的应助被chenrao采纳,获得10
4秒前
慕青的应助被寒酥采纳,获得10
4秒前
4秒前
鲤鱼雁风完成签到,获得积分10
4秒前
5秒前
wanci的应助被白色采纳,获得10
5秒前
5秒前
星辰大海的应助被雨雨青青采纳,获得10
5秒前
Elenaiga完成签到 ,获得积分10
5秒前
zhzha发布了新的文献求助10
5秒前
寒冷黎云发布了新的文献求助10
6秒前
ZM9450完成签到,获得积分10
6秒前
6秒前
终梦的应助被wyn采纳,获得10
6秒前
7秒前
7秒前
嘴遁老铁叽完成签到,获得积分10
7秒前
单薄的寄灵完成签到 ,获得积分20
7秒前
8秒前
小k完成签到,获得积分10
8秒前
科研通AI6.2的应助被xxj采纳,获得10
8秒前
piii完成签到 ,获得积分10
8秒前
鲤鱼雁风发布了新的文献求助10
9秒前
小菜发布了新的文献求助10
10秒前
健忘冰蝶发布了新的文献求助10
10秒前
kk发布了新的文献求助10
11秒前
11秒前
英姑的应助被有人喜欢蓝采纳,获得10
11秒前
mlg1552003发布了新的文献求助10
11秒前
12秒前
leilei完成签到,获得积分20
12秒前
复杂的不弱完成签到,获得积分10
12秒前
搜集达人的应助被少年采纳,获得10
12秒前
nju发布了新的文献求助10
12秒前
慕青的应助被积极亦竹采纳,获得10
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8175556
求助须知:如何正确求助?哪些是违规求助? 9567240
关于积分的说明 21791502
捐赠科研通 7770174
什么是DOI,文献DOI怎么找? 3431868
关于科研通互助平台的介绍 2556244
邀请新用户注册赠送积分活动 2477299